Funding for this research was provided by:
Text and Data Mining valid from 2020-02-21
Received: 11 October 2019
Accepted: 6 February 2020
First Online: 21 February 2020
Ethics approval and consent to participate
: This study received Research Ethics Board clearance from Queen’s University Health Sciences and affiliated teaching hospitals Research Ethics Board (DMED-2125-18).
: JB has been on the Speaker’s Bureau for ALK-Abello, Aralez, Merck, Mylan, Novartis, Pediapharm, Pfizer, and Takeda; has received grant support from Aralez and Mylan and has been an advisor to Takeda and Novartis. SC has been on the speaker’s bureau for Merck, Meda/Mylan, Sanofi, Johnson & Johnson, Nutricia, Pfizer, and Tribute/Aralez; has been an advisor to Merck, Meda/Mylan, Sanofi, GSK, Tribute/Aralez, Pediapharm, Stallergenes Greer, and ALK; and received research funding from Cephalon. FG declares no competing interests. AKE has been on the Speaker’s Bureau for ALK-Abello, Aralez, AstraZeneca, Meda, Merck, Mylan, Novartis, Pediapharm, Pfizer, and Takeda; received research funding from Adiga Life Sciences Inc, AllerGen NCE, Circassia Ltd, GSK, Green Cross, JP Bickell Foundation, Merck, Novartis, Pfizer, Sanofi, and SunPharma, and has been an advisor to ALK-Abello, Bayer, Circassia Ltd., Merck, Mylan, Novartis, Pediapharm, Pfizer and Johnson & Johnson. MM has been on the Speaker’s Bureau for Aralez, Novartis and Pediapharm.